PRP/OSI sustained-release Macugen collaboration
A PR Pharmaceuticals/OSI collaboration to develop sustained-release Macugen, announced Jan. 11, grants OSI rights to license PRP's ProPhase encapsulation technology. Under the agreement, PRP will develop the new formulations of the neovascular age-related macular degeneration therapy and test article for non-clinical and clinical trials, while OSI will manage clinical development, manufacturing and marketing. PRP will receive an undisclosed up-front payment from OSI, which recently acquired Macugen (pegaptanib) developer Eyetech, as well as future milestone payments and royalties on net sales of any product resulting from the collaboration. Macugen is expected to face competition in the AMD market from Genentech's Lucentis in early 2006 (1"The Pink Sheet" Nov. 28, 2005, p. 4)...
You may also be interested in...
An early 2006 launch of Genentech's wet age-related macular degeneration candidate Lucentis could impact sales of OSI/Eyetech's competing therapy, Macugen, by an estimated $75 mil. that year, OSI said
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.